SAN DIEGO–(BUSINESS WIRE)–Candid Therapeutics, Inc. (“Candid”), a clinical stage biotechnology company positioned to lead the development of T-cell engagers for autoimmune diseases, appointed repeatedly successful industry veterans, Angie You, Ph.D. and Dan Puckett, to its board of directors.
“T-cell engagers have the potential to tranform the treatment of many autoimmune diseases. Ken has assembled a world-class management team and an diverse portfolio of assets. I am excited to partner with him, the Candid board and management team to support the company in it’s ambitious growth plans,” said Dr. You.
“Ken and team have made tremendous progress in a very short timeframe. I believe Candid is well positioned to be the leader in developing T cell engagers for B-cell depletion. I’ve worked with Ken in the past and look forward to leveraging my background to help scale the company,” said Mr. Puckett.
“Angie and Dan are proven leaders with a track record of scaling organizations and advancing innovative products into development and commercialization. I have been fortunate to have worked with each of them in the past and am delighted to welcome them to our board of directors. They will both be an invaluable resource to Candid as we strive to build the leading company in treating autoimmune diseases,” said Ken Song, Chairman, President and CEO of Candid Therapeutics.
